

2

Docket No. GEN-T111XC3D2  
Serial No. 09/901,484In the Claims

1-49 (Canceled).

50 (Currently Amended). A recombinant, purified or isolated polynucleotide comprising:

- a) at least 500 consecutive nucleotides of SEQ ID NO: 179;
- b) SEQ ID NO: 179;
- c) a contiguous span of at least ~~12, 15, 18, 20, 25, 30, 35, 40~~, 50, 60, 70, 80, 90, 100, 150, 200, or 500 nucleotides of SEQ ID NO: 179, wherein said contiguous span comprises at least 1 of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, or 55666-56146;
- d) a contiguous span of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, 55666-56146 or a

3

Docket No. GEN-T111XC3D2  
Serial No. 09/901,484

complementary span of nucleotides to said contiguous span of nucleotide positions;

- c) a contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179 or a contiguous span of nucleotides that is complementary to said contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179, wherein:
- i) X is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30;
  - ii) Y is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30; and
  - iii) N is equal to one of the following values: 2159; 2443; 4452; 5733; 8438; 11843; 1983; 12080; 12221; 12947; 13147; 13194; 13310; 13342; 13367; 13594; 13680; 13902; 16231; 16388; 17608; 18034; 18290; 18786; 22835; 22872; 25183; 25192; 25614; 26911; 32703; 34491; 34756; 34934; 5160; 39897; 40598; 40816; 40947; 45783; 47929; 48206; 48207; 49282; 50037; 50054; 50101; 50220; 50440; 50562; 50653; 50660; 50745; 50885; 51249; 51333; 51435; 51468; 51515; 51557; 51566; 51632; 51666; 52016; 52096; 52151; 52282; 52348; 52410; 52580; 52712; 52772; 52860; 53092; 53272; 53389; 53511; 53600; 53665; 53815; 54365; or 54541; or
- f) a polynucleotide of at least 500 consecutive nucleotides that is complementary to a polynucleotide as set forth in a), b), or c).

51 (Currently Amended). A vector comprising a polynucleotide:

- a) comprising at least 500 consecutive nucleotides of SEQ ID NO: 179;
- b) comprising SEQ ID NO: 179;
- c) comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, or 500 nucleotides of SEQ ID NO: 179, wherein said contiguous span comprises at least 1 of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572,

4

Docket No. GEN-T111XC3D2  
Serial No. 09/901,484

- 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, or 55666-56146;
- d) comprising a contiguous span of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, 55666-56146 or a complementary span of nucleotides to said contiguous span of nucleotide positions;
- e) comprising a contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179 or a contiguous span of nucleotides that is complementary to said contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179, wherein:
- i) X is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30;
  - ii) Y is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30; and
  - iii) N is equal to one of the following values: 2159; 2443; 4452; 5733; 8438; 11843; 1983; 12080; 12221; 12947; 13147; 13194; 13310; 13342; 13367; 13594; 13680; 13902; 16231; 16388; 17608; 18034;

5

Docket No. GEN-T111XC3D2

Serial No. 09/901,484

18290; 18786; 22835; 22872; 25183; 25192; 25614; 26911; 32703;  
34491; 34756; 34934; 5160; 39897; 40598; 40816; 40947; 45783;  
47929; 48206; 48207; 49282; 50037; 50054; 50101; 50220; 50440;  
50562; 50653; 50660; 50745; 50885; 51249; 51333; 51435; 51468;  
51515; 51557; 51566; 51632; 51666; 52016; 52096; 52151; 52282;  
52348; 52410; 52580; 52712; 52772; 52860; 53092; 53272; 53389;  
53511; 53600; 53665; 53815; 54365; or 54541; or

- f) comprising a polynucleotide of at least 500 consecutive nucleotides that is complementary to a polynucleotide as set forth in a), b), or c).

52 (Currently Amended). A host cell comprising:

1) a polynucleotide comprising:

- a) at least 500 consecutive nucleotides of SEQ ID NO: 179;
- b) SEQ ID NO: 179;
- c) a contiguous span of at least ~~12, 15, 18, 20, 25, 30, 35,~~ 40, 50, 60, 70, 80, 90, 100, 150, 200, or 500 nucleotides of SEQ ID NO: 179, wherein said contiguous span comprises at least 1 of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, or 55666-56146;
- d) a contiguous span of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302,

6

Docket No. GEN-T111XC3D2

Serial No. 09/901,484

14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, 55666-56146 or a complementary span of nucleotides to said contiguous span of nucleotide positions;

- o) a contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179 or a contiguous span of nucleotides that is complementary to said contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179, wherein:

- i) X is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30;
- ii) Y is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30; and
- iii) N is equal to one of the following values: 2159; 2443; 4452; 5733; 8438; 11843; 1983; 12080; 12221; 12947; 13147; 13194; 13310; 13342; 13367; 13594; 13680; 13902; 16231; 16388; 17608; 18034; 18290; 18786; 22835; 22872; 25183; 25192; 25614; 26911; 32703; 34491; 34756; 34934; 5160; 39897; 40598; 40816; 40947; 45783; 47929; 48206; 48207; 49282; 50037; 50054; 50101; 50220; 50440; 50562; 50653; 50660; 50745; 50885; 51249; 51333; 51435; 51468; 51515; 51557; 51566; 51632; 51666; 52016; 52096; 52151; 52282; 52348; 52410; 52580; 52712; 52772; 52860; 53092; 53272; 53389; 53511; 53600; 53665; 53815; 54365; or 54541; or

- f) a polynucleotide of at least 500 consecutive nucleotides that is complementary to a polynucleotide as set forth in a), b), or c); or

2) a vector comprising a polynucleotide:

- a) comprising at least 500 consecutive nucleotides of SEQ ID NO: 179;

J:\GEN-T111XC3D2\Amend-Resp\AF-Amd.doc\DNB\sl

7

Docket No. GEN-T111XC3D2  
Serial No. 09/901,484

- b) comprising SEQ ID NO: 179;
- c) comprising a contiguous span of at least ~~12, 15, 18, 20, 25, 30, 35, 40, 50, 60,~~ 70, 80, 90, 100, 150, 200, or 500 nucleotides of SEQ ID NO: 179, wherein said contiguous span comprises at least 1 of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, or 55666-56146;
- d) comprising a contiguous span of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, 55666-56146 or a complementary span of nucleotides to said contiguous span of nucleotide positions;
- e) comprising a contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179 or a contiguous span of nucleotides that is complementary to said contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179, wherein:

J:\AGENT\111XC3D2\Amend-Resp\AF-Amd.doc\10NH\sl

8

Docket No. GEN-T111XC3D2

Serial No. 09/901,484

- i) X is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30;
- ii) Y is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30; and
- iii) N is equal to one of the following values: 2159; 2443; 4452; 5733; 8438; 11843; 1983; 12080; 12221; 12947; 13147; 13194; 13310; 13342; 13367; 13594; 13680; 13902; 16231; 16388; 17608; 18034; 18290; 18786; 22835; 22872; 25183; 25192; 25614; 26911; 32703; 34491; 34756; 34934; 5160; 39897; 40598; 40816; 40947; 45783; 47929; 48206; 48207; 49282; 50037; 50054; 50101; 50220; 50440; 50562; 50653; 50660; 50745; 50885; 51249; 51333; 51435; 51468; 51515; 51557; 51566; 51632; 51666; 52016; 52096; 52151; 52282; 52348; 52410; 52580; 52712; 52772; 52860; 53092; 53272; 53389; 53511; 53600; 53665; 53815; 54365; or 54541; or
- f) comprising a polynucleotide of at least 500 consecutive nucleotides that is complementary to a polynucleotide as set forth in a), b), or c).

53 (Currently Amended). A nonhuman host animal or mammal comprising:

1) a polynucleotide comprising:

- a) at least 500 consecutive nucleotides of SEQ ID NO: 179;
- b) SEQ ID NO: 179;
- c) a contiguous span of at least ~~12, 15, 18, 20, 25, 30, 35,~~ 40, 50, 60, 70, 80, 90, 100, 150, 200, or 500 nucleotides of SEQ ID NO: 179, wherein said contiguous span comprises at least 1 of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-

J:\AGENT\111XC3D2\Amend-Rcsp\AF-Amd.doc\DNB\A

9

Docket No. GEN-T111XC3D2  
Serial No. 09/901,484

47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, or 55666-56146;

- d) a contiguous span of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, 55666-56146 or a complementary span of nucleotides to said contiguous span of nucleotide positions;
- e) a contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179 or a contiguous span of nucleotides that is complementary to said contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179, wherein:
- i) X is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30;
  - ii) Y is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30; and
  - iii) N is equal to one of the following values: 2159; 2443; 4452; 5733; 8438; 11843; 1983; 12080; 12221; 12947; 13147; 13194; 13310; 13342; 13367; 13594; 13680; 13902; 16231; 16388; 17608; 18034; 18290; 18786; 22835; 22872; 25183; 25192; 25614; 26911; 32703; 34491; 34756; 34934; 5160; 39897; 40598; 40816; 40947; 45783; 47929; 48206; 48207; 49282; 50037; 50054; 50101; 50220; 50440; 50562; 50653; 50660; 50745; 50885; 51249; 51333; 51435; 51468; 51515; 51557; 51566; 51632; 51666; 52016; 52096; 52151; 52282; 52348; 52410; 52580; 52712; 52772; 52860; 53092; 53272; 53389;

J:\AGENT\111XC3D2\Amentf-Resp\AF-Amd.doc/DND\sl



10

Docket No. GEN-T111XC3D2

Serial No. 09/901,484

53511; 53600; 53665; 53815; 54365; or 54541; or

- f) a polynucleotide of at least 500 consecutive nucleotides that is complementary to a polynucleotide as set forth in a), b), or c); or

2) a vector comprising a polynucleotide:

- a) comprising at least 500 consecutive nucleotides of SEQ ID NO: 179;
- b) comprising SEQ ID NO: 179;
- c) comprising a contiguous span of at least ~~12, 15, 18, 20, 25, 30, 35, 40, 50, 60,~~ 70, 80, 90, 100, 150, 200, or 500 nucleotides of SEQ ID NO: 179, wherein said contiguous span comprises at least 1 of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, or 55666-56146;
- d) comprising a contiguous span of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, 55666-56146 or a complementary span of nucleotides to said contiguous span of nucleotide positions;

11

Docket No. GEN-T111XC3D2  
Serial No. 09/901,484

- e) comprising a contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179 or a contiguous span of nucleotides that is complementary to said contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179, wherein:
- i) X is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30;
  - ii) Y is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30; and
  - iii) N is equal to one of the following values: 2159; 2443; 4452; 5733; 8438; 11843; 1983; 12080; 12221; 12947; 13147; 13194; 13310; 13342; 13367; 13594; 13680; 13902; 16231; 16388; 17608; 18034; 18290; 18786; 22835; 22872; 25183; 25192; 25614; 26911; 32703; 34491; 34756; 34934; 5160; 39897; 40598; 40816; 40947; 45783; 47929; 48206; 48207; 49282; 50037; 50054; 50101; 50220; 50440; 50562; 50653; 50660; 50745; 50885; 51249; 51333; 51435; 51468; 51515; 51557; 51566; 51632; 51666; 52016; 52096; 52151; 52282; 52348; 52410; 52580; 52712; 52772; 52860; 53092; 53272; 53389; 53511; 53600; 53665; 53815; 54365; or 54541; or
- f) comprising a polynucleotide of at least 500 consecutive nucleotides that is complementary to a polynucleotide as set forth in a), b), or c).

54-55 (Canceled).

56 (Previously Presented). The isolated, purified, or recombinant polynucleotide of claim 50, further comprising a label.

57 (Previously Presented). The isolated, purified, or recombinant polynucleotide of claim 50, wherein said polynucleotide is attached to a solid support.

J:\AGENT\T111XC3D2\Amend-Resp\AF-Amend\due\DNB\sl

12

Docket No. GEN-T111XC3D2

Serial No. 09/901,484

58 (Previously Presented). A random or addressable array of polynucleotides comprising at least one polynucleotide according to claim 50.

59 (Previously Presented). The isolated, purified, or recombinant polynucleotide according to claim 50, wherein said polynucleotide is at least 500 consecutive nucleotides of SEQ ID NO: 179.

60 (Previously Presented). The isolated, purified, or recombinant polynucleotide according to claim 50, wherein said polynucleotide is SEQ ID NO: 179.

61 (Currently Amended). The isolated, purified, or recombinant polynucleotide according to claim 50, wherein said polynucleotide is a contiguous span of at least ~~12, 15, 18, 20, 25, 30, 35, 40,~~ 50, 60, 70, 80, 90, 100, 150, 200, or 500 nucleotides of SEQ ID NO: 179, wherein said contiguous span comprises at least 1 of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599, 54516-55209, or 55666-56146.

62 (Previously Presented). The isolated, purified, or recombinant polynucleotide according to claim 50, wherein said polynucleotide is a contiguous span of the following nucleotide positions of SEQ ID NO: 179: 1-2324, 2852-2936, 3204-3249, 3456-3572, 3899-4996, 5028-6086, 6310-8710, 9136-11170, 11534-12104, 12733-13163, 13206-14150, 14191-14302, 14338-14359, 14788-15589, 16050-16409, 16440-21718, 21959-22007, 22086-23057, 23488-23712, 23832-24099, 24165-24376, 24429-24568, 24607-25096, 25127-25269, 25300-27576, 27612-29217, 29415-30776, 30807-30986, 31628-32658, 32699-36324, 36772-39149, 39184-40269, 40580-40683, 40844-41048, 41271-43539, 43570-47024, 47510-48065, 48192-49692, 49723-50174, 52626-53599,

J:\GEN\T111XC3D2\Amend-Resp\AF-Amd.doc\DN13\sl

13

Docket No. GEN-T111XC3D2

Serial No. 09/901,484

54516-55209, 55666-56146 or a complementary span of nucleotides to said contiguous span of nucleotide positions.

63 (Previously Presented). The isolated, purified, or recombinant polynucleotide according to claim 50, wherein said polynucleotide is a contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179 or a contiguous span of nucleotides that is complementary to said contiguous span of nucleotides selected from a group nucleotide sequences spanning from position N-X to position N+Y of SEQ ID NO: 179, wherein:

- i) X is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30;
- ii) Y is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30; and
- iii) N is equal to one of the following values: 2159; 2443; 4452; 5733; 8438; 11843; 1983; 12080; 12221; 12947; 13147; 13194; 13310; 13342; 13367; 13594; 13680; 13902; 16231; 16388; 17608; 18034; 18290; 18786; 22835; 22872; 25183; 25192; 25614; 26911; 32703; 34491; 34756; 34934; 5160; 39897; 40598; 40816; 40947; 45783; 47929; 48206; 48207; 49282; 50037; 50054; 50101; 50220; 50440; 50562; 50653; 50660; 50745; 50885; 51249; 51333; 51435; 51468; 51515; 51557; 51566; 51632; 51666; 52016; 52096; 52151; 52282; 52348; 52410; 52580; 52712; 52772; 52860; 53092; 53272; 53389; 53511; 53600; 53665; 53815; 54365; or 54541.

64 (Previously Presented). The isolated, purified, or recombinant polynucleotide according to claim 50, wherein said polynucleotide is a polynucleotide of at least 500 consecutive nucleotides that is complementary to a polynucleotide as set forth in claim 60.

65 (Previously Presented). The isolated, purified, or recombinant polynucleotide according to claim 50, wherein said polynucleotide is a polynucleotide of at least 500 consecutive nucleotides that is complementary to a polynucleotide as set forth in claim 61.

14

Docket No. GEN-T111XC3D2

Serial No. 09/901,484

66 (Previously Presented). The isolated, purified, or recombinant polynucleotide according to claim 50, wherein said polynucleotide is a polynucleotide of at least 500 consecutive nucleotides that is complementary to a polynucleotide as set forth in claim 62.

J:\GEN-T111XC3D2\Amend-Resp\A1-Amd doc\DN13\sl